title: Celecoxib desensitization:  continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
abstract: Cox-2 inhibitors have been identified as promising candidates for cancer therapy. Several studies have recently proposed the use of celecoxib in long-term low-intensity chemotherapy protocols for recurrent tumors. However, drug-induced hypersensitivity reactions may force discontinuation of the medication and, thus, significantly complicate successful care. Here, we report on celecoxib desensitization after a celecoxib-induced skin reaction, thereby allowing the continuation of temozolomide/celecoxib chemotherapy in a young patient with recurrent astrocytoma.
authors.affiliation: Department of Dermatology, Charité-Universitätsmedizin Berlin, Berlin, Germany. guido.burbach@charite.de
authors.forename: Guido J
authors.initials: GJ
authors.lastname: Burbach
authors.forename: Peter
authors.initials: P
authors.lastname: Vajkoczy
authors.forename: Torsten
authors.initials: T
authors.lastname: Zuberbier
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male; D011720:Pyrazoles / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D003606:Dacarbazine; D000068579:Celecoxib; D000077204:Temozolomide